Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
8
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
investing
8
×
life sciences
national
national blog main
national top stories
new york blog main
8
×
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
8
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
8
×
texas top stories
wisconsin blog main
wisconsin top stories
startups
cancer immunotherapy
clinical trials
deals
fda
pfizer
eli lilly
roche
vertex pharmaceuticals
alexion pharmaceuticals
bristol-myers squibb
What
roundup
8
×
bio
drug
ahead
alzheimer’s
annual
asco
attention
biotech
companies
days
drugs
fda
growing
new
pharmaceutical
plan
prices
typically
advantages
alliance
ambien
american
approved
assessed
attendees
bails
bar
brand
branded
bridgebio
brings
bristol
buy
calls
camp’s
cancer
capital
car
cash
Language
unset
Current search:
investing
×
roundup
×
" san francisco blog main "
×
" new york blog main "
×
" texas blog main "
×
cancer
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More